Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rupatadine - Medexus Pharmaceuticals

Drug Profile

Rupatadine - Medexus Pharmaceuticals

Alternative Names: Alergoliber; Rupafin; Rupall; Rupatadine fumarate; TK-041; UR 12592

Latest Information Update: 20 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Uriach
  • Developer Medexus Pharmaceuticals; Teikoku Seiyaku; Uriach
  • Class Antiallergics; Dibenzocycloheptenes; Nonsedating antihistamines; Piperidines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Platelet activating factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Perennial allergic rhinitis; Seasonal allergic rhinitis; Urticaria
  • Registered Pruritus
  • Discontinued Atopic dermatitis; Dermatitis

Most Recent Events

  • 13 Dec 2018 Pediapharm is now called Medexus Pharmaceuticals
  • 22 Nov 2017 Teikoku Seiyaku and Mitsubishi Tanabe Pharma Corporation intend to launch rupatadine fumarate (Rupafin®) in Japan on November 27, 2017
  • 27 Sep 2017 Registered for Pruritus, Seasonal allergic rhinitis, Perennial allergic rhinitis and Urticaria in Japan (PO, Tablet) (PMDA website)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top